PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau

PERATION TREATY (PCT)

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION IREATY (PCT)

(51) International Patent Classification ⁶: C12Q 1/68, C07D 473/16

A1

(11) International Publication Number:

WO 99/32660

1

(43) International Publication Date:

1 July 1999 (01.07.99)

(21) International Application Number:

PCT/US98/26925

(22) International Filing Date:

18 December 1998 (18.12.98)

(30) Priority Data:

60/068,289

19 December 1997 (19,12,97) US

(71) Applicant (for all designated States except US): AFFYMETRIX [US/US]; 3380 Central Expressway, Santa Clara, CA 95051 (US).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): LOCKHART, David, J. [US/US]; Affymetrix, 3380 Central Expressway, Santa Clara, CA 95091 (US). WODICKA, Lisa [US/US]; Affymetrix, Inc., 3380 Central Expressway, Santa Clara, CA 95051 (US). HO, Ming, Hsui [US/US]; Affymetrix, Inc., 3380 Central Expressway, Santa Clara, CA 95051 (US).
- (74) Agents: KAGAN, Sarah, A. et al.; Banner & Witcoff, Ltd., 11th floor, 1001 G Street, N.W., Washington, DC 20001-4597 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: EXPLOITING GENOMICS IN THE SEARCH FOR NEW DRUGS

(57) Abstract

The cellular effects of potentially therapeutic compounds are characterized in mammalian cells and yeast. In the latter case the effects can be characterized on a genome-wide scale by monitoring changes in messenger RNA levels in treated cells with high-density oligonucleotide probe arrrays.

48 30 FR

1